Nurix Therapeutics, Inc.
Regulated industrySells to businessesDevelopment stageTags from an AI model reading the company description.
Key Metrics
- Previous Close
- $14.24
- 52-Week Range
- $12.61 – $28.23
- Market Cap
- $1.54B
- P/E (TTM)
- 5.85
- EPS (TTM)
- 2.41
- Dividend Yield
- 0.00%
Advanced Metrics
- Price/Book
- 1.59
- PEG Ratio
- —
- Return on Equity
- 43.99%
- Return on Assets
- 21.08%
- Gross Margin
- 52.41%
- Operating Margin
- 41.27%
- Profit Margin
- 42.01%
- Current Ratio
- 8.44
- Debt/Equity
- 0.07
- Total Debt
- $65.33M
- Free Cash Flow
- $233.34M
- Revenue Growth
- 8426.30%
- Earnings Growth
- —
- Enterprise Value
- $557.50M
Market Snapshot
About
Nurix Therapeutics, Inc. is a clinical-stage biotechnology company developing targeted protein degradation therapies for cancer and immune disorders. The company uses its proprietary DELigase platform to discover small molecules that harness the ubiquitin-proteasome system to degrade disease-causing proteins. Nurix has multiple drug candidates in clinical development targeting difficult-to-treat cancers and inflammatory diseases.